NASDAQ:EOLSEvolus Stock Price, Forecast & News

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS shares have decreased by 37.1% and is now trading at $3.72.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Evolus.

Evolus is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Evolus.

Evolus Inc (NASDAQ:EOLS) posted its earnings results on Monday, May, 11th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.03. The company had revenue of $10.50 million for the quarter, compared to analysts' expectations of $16.91 million. Evolus had a negative net margin of 217.51% and a negative return on equity of 197.30%.
View Evolus' earnings history.

7 equities research analysts have issued 1-year price targets for Evolus' shares. Their forecasts range from $3.00 to $25.00. On average, they anticipate Evolus' share price to reach $9.43 in the next year. This suggests a possible upside of 153.5% from the stock's current price.
View analysts' price targets for Evolus.

News articles about EOLS stock have been trending neutral this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evolus earned a news impact score of 0.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Evolus.

Evolus saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 3,790,000 shares, a decrease of 37.8% from the April 15th total of 6,090,000 shares. Based on an average daily trading volume, of 629,000 shares, the short-interest ratio is currently 6.0 days. Currently, 17.3% of the shares of the stock are sold short.
View Evolus' Short Interest.

Some companies that are related to Evolus include Kala Pharmaceuticals (KALA), Urogen Pharma (URGN), Tocagen (TOCA), Athersys (ATHX), Homology Medicines (FIXX), Ardelyx (ARDX), Prothena (PRTA), BioSpecifics Technologies (BSTC), AnaptysBio (ANAB), Protagonist Therapeutics (PTGX), DURECT (DRRX), XBiotech (XBIT), BioDelivery Sciences International (BDSI), AC Immune (ACIU) and Neoleukin Therapeutics (NLTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Celadon Group (CGI), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OrganiGram (OGI) and Aldeyra Therapeutics (ALDX).

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by many different retail and institutional investors. Top institutional investors include Laidlaw Wealth Management LLC (2.51%), Alyeska Investment Group L.P. (0.99%), Bank of New York Mellon Corp (0.25%), Virtu Financial LLC (0.21%), UBS Group AG (0.19%) and Stifel Financial Corp (0.19%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik.
View institutional ownership trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc..
View insider buying and selling activity for Evolus.

EOLS stock was bought by a variety of institutional investors in the last quarter, including Laidlaw Wealth Management LLC, Virtu Financial LLC, Alyeska Investment Group L.P., Jefferies Group LLC, PDT Partners LLC, Advisor Group Holdings Inc., Algert Global LLC, and UBS Group AG. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Michael M Jafar, Simone Blank, and Vikram Malik.
View insider buying and selling activity for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $3.72.

Evolus has a market capitalization of $125.54 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

The official website for Evolus is www.evolus.com.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]